Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795039 | 0.79 | ERN1 (0.38) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL23457275 | 0.78 | NFE2L2 (0.56) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3713124 | 0.78 | NFE2L2 (0.56) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL320615 | 0.77 | NFE2L2 (0.62) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4090323 | 0.77 | NFE2L2 (0.62) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2118262 | 0.76 | NFE2L2 (0.68) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL28099411 | 0.76 | NFE2L2 (0.54) | NFE2L2CYP1A2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5074495 | 0.73 | TRIM24 (0.52) | NFE2L2TRPA1 | |
| SCHEMBL5407394 | 0.73 | CES2 (0.44) | CYP1A2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8112257 | 0.73 | NFE2L2 (0.50) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765728-B2 | [1,5]-diazocin derivatives | MELLITECH (FR) | 2014-07-01 | — | — | US | disclosed |
| EP-2501685-A1 | [1,5]-DIAZOCIN DERIVATIVES | Mellitech (FR) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | MELLITECH (FR) | 2012-09-06 | — | — | US | disclosed |
| WO-2011058193-A1 | [1,5]-DIAZOCIN DERIVATIVES | MELLITECH (FR) | 2011-05-19 | — | — | WO | disclosed |
| EP-1796675-A4 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| CN-101035537-A | Compositions and methods for treating ocular diseases | MERCK & CO INC (US) | 2007-09-12 | — | — | CN | disclosed |
| EP-1796675-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006039252-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-6127388-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-5998440-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| EP-0906308-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| EP-0861244-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997045426-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997018201-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| CN-1034924-A | quinoline, quinazoline and cinnoline derivatives | LILLY CO ELI (US) | 1989-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | NFE2L2 1005/4885CYP1A2 4845/4885GRIN2D 4389/4885 |
| US-20120225892-A1 | [1,5]-Diazocin Derivatives | IAPP, INSR, GLP1R | NFE2L2 1294/4885CYP1A2 2743/4885GRIN2D 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.